Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on July 29, 2016, regarding an event that occurred on July 28, 2016. The filing addresses a significant legal development concerning the company's product ARISTADA (aripiprazole lauroxil).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event and does not contain financial performance data.
Material Changes and Legal Developments
On July 28, 2016, the United States District Court for the District of Columbia issued an opinion in favor of Alkermes and the U.S. Food and Drug Administration (FDA). The court:
- Affirmed the FDA's decision to approve ARISTADA for the treatment of schizophrenia.
- Denied the action for declaratory and injunctive relief filed by Otsuka Pharm. Co. and its affiliates (collectively "Otsuka").
Otsuka retains the right to appeal this decision within 60 days.
Outlook, Risks, and Contingencies
While the court ruling is favorable, a material contingency remains: Otsuka has 60 days to appeal the decision. The outcome of any potential appeal could impact the commercialization timeline or legal standing of ARISTADA.
Investor Verification Checklist
- Verify the status of Otsuka's potential appeal within the 60-day window.
- Confirm the commercial launch status of ARISTADA following the court's affirmation of FDA approval.
- Review subsequent filings for any updates on the litigation or financial impact of the approval.